Boston-based Third Rock Ventures is announcing, along with GlaxoSmithKline SR One venture arm, that they are putting $52 million to work in a Series A financing for the rather aptly named Decibel Therapeutics. Third Rock partner Kevin Starr is the chairman and interim CEO. In typical Third Rock fashion, it rounded up a who’s who of hearing loss researchers from Massachusetts Eye and Ear (M. Charles Liberman and Albert Edge), the University of Michigan (Gabriel Corfas) and the Scripps Research Institute (Ulrich Müller). http://www.forbes.com/sites/luketim...ird-rock-pumps-52m-into-hearing-loss-startup/ http://www.xconomy.com/boston/2015/...-put-52m-into-decibel-to-battle-hearing-loss/ From the above link: "With success Decibel will move to more prevalent problems, like a consistent ringing in the ears called tinnitus, or age-related hearing loss, both of which affect millions across the globe." They're 3 years out from any sort of hearing related drugs being tested, but nice to see another player in the game!